A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Aliskiren; Atenolol
- Indications Essential hypertension; Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 17 Nov 2006 New trial record.